Piretanide

Piretanide

SCHEMBL49473

NS(=O)(=O)c1cc(C(=O)O)cc(N2CCCC2)c1Oc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 1.00
HSD17B10 Q99714 4/20 1.00
ALDH1A1 P00352 3/20 1.00
HPGD P15428 3/20 1.00
USP2 O75604 2/20 1.00
LMNA P02545 2/20 1.00
HIF1A Q16665 2/20 1.00
SLC6A4 P31645 1/20 1.00
TSHR P16473 2/20 0.52
CA2 P00918 1/20 0.52
BLM P54132 1/20 0.52
SLC12A2 P55011 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
ERAP1 Q9NZ08 2/20 0.43
ERAP2 Q6P179 1/20 0.43
GAA P10253 3/20 0.41
POLB P06746 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MMP2 P08253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piretanide SCHEMBL30230376 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDUSP2
Piretanide SCHEMBL1741994 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDUSP2
SCHEMBL2741891 0.99 KDM4E (0.98) KDM4EHSD17B10ALDH1A1HPGDUSP2
Piretanide SCHEMBL9837127 0.99 KDM4E (0.98) KDM4EHSD17B10ALDH1A1HPGDUSP2
Piretanide SCHEMBL18075706 0.98 KDM4E (0.95) KDM4EHSD17B10ALDH1A1HPGDUSP2
Piretanide SCHEMBL7895002 0.98 KDM4E (0.95) KDM4EHSD17B10ALDH1A1HPGDUSP2
SCHEMBL11542770 0.98 KDM4E (0.95) KDM4EHSD17B10ALDH1A1HPGDUSP2
SCHEMBL11546942 0.95 LMNA (0.91) KDM4EHSD17B10ALDH1A1HPGDUSP2
SCHEMBL231996 0.92 ALDH1A1 (0.85) KDM4EHSD17B10ALDH1A1HPGDUSP2
Piretanide SCHEMBL250849 0.92 KDM4E (0.84) KDM4EHSD17B10ALDH1A1HPGDUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7253 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090360-A1 FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC. (US) 2026-04-30 WO claimed
US-20260108529-A1 FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC (US) 2026-04-23 US claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
EP-4710928-A2 METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN Chinook Therapeutics, Inc. (US) 2026-03-18 EP claimed
US-20250352511-A1 METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN CHINOOK THERAPEUTICS INC (US) 2025-11-20 US claimed
EP-4525857-A1 METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN Chinook Therapeutics, Inc. (US) 2025-03-26 EP claimed
US-20250057876-A1 METHODS FOR TREATING AND/OR PREVENTING LYMPHANGIOGENESIS-ASSOCIATED DISEASES BY USING GOLD NANOCLUSTERS GOLDRED NANOBIOTECH CO., LTD. (TW) 2025-02-20 US claimed
EP-3419612-B1 HETEROCYCLIC SMALL MOLECULE INHIBITORS OF PENDRIN ION EXCHANGE AND PHARMACEUTICAL COMPOSITIONS UNIV CALIFORNIA (US) 2024-11-06 EP claimed
US-12121509-B2 Methods of improving renal function CHINOOK THERAPEUTICS, INC. (US) 2024-10-22 US claimed
US-20240294986-A1 PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2024-09-05 US claimed
EP-0499142-A2 Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs HOECHST AKTIENGESELLSCHAFT (DE) 1992-08-19 EP claimed
EP-0243891-B1 A LAMINAR STRUCTURE FOR ADMINISTERING A CHEMICAL AT A CONTROLLED RELEASE RATE HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1991-08-14 EP claimed
EP-0247507-B1 COMPOSITION FOR TRANSDERMAL THERAPEUTICAL SYSTEMS OF HIGH-CEILING DIURETICS, AND PROCESS FOR PRODUCING IT HOECHST AKTIENGESELLSCHAFT (DE) 1991-01-09 EP claimed
EP-0386688-A1 Method for preparing hydrogel preparations and xerogel preparations HOECHST JAPAN LIMITED (JP) 1990-09-12 EP claimed
US-4931281-A Laminar structure for administering a chemical at a controlled release rate HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1990-06-05 US claimed
EP-0243891-A2 A laminar structure for administering a chemical at a controlled release rate HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1987-11-04 EP claimed
US-4564625-A DIURETICS ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1986-01-14 US claimed
US-4557934-A ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE THE PROCTER & GAMBLE COMPANY (US) 1985-12-10 US claimed
EP-0043548-B1 SALT OF FUROSEMIDE OR PIRETANIDE AS ACID COMPONENT AND PENBUTOLOL AS BASE COMPONENT AND PHARMACEUTICAL COMPOSITION CONTAINING BOTH OF THE SAID COMPONENTS HOECHST AKTIENGESELLSCHAFT (DE) 1984-07-25 EP claimed
US-4010273-A DIURETICS, SALURETICS HOECHST AKTIENGESELLSCHAFT (DT) 1977-03-01 US claimed